There's no doubt that there will be plenty of choices. The drug is known to work on over 100 different types of cancer. I think the point is to isolate the cancers that exhibit the strongest reaction to Coramsine and pursue those through phase II. This will give the best chance of a positive (and potentially dramatic) outcome.
- Forums
- ASX - By Stock
- SBP
- genentech up $11 billion
SBP
solbec pharmaceuticals limited
genentech up $11 billion, page-7
Add SBP (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
NRZ
NEURIZER LTD
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
Previous Video
Next Video
SPONSORED BY The Market Online